Estimating Appropriate ICD Shocks After Primary Prevention Implantation

An implantable cardioverter-defibrillator (ICD) placed for primary prevention is intended to treat a potentially fatal ventricular tachyarrhythmia before the patient has experienced cardiac arrest or sustained ventricular tachycardia. When the device later delivers therapy for ventricular tachycardia or ventricular fibrillation, that treatment is usually called an appropriate shock. Estimating this risk can help clinicians discuss expected benefit, follow-up intensity and the balance between arrhythmic protection and competing illness.

The challenge is that an ICD shock is an imperfect endpoint. It may terminate a life-threatening rhythm, yet it can also cause pain, anxiety, myocardial injury and repeated hospital presentations. Risk scores therefore need to be interpreted alongside left ventricular function, heart failure status, coronary disease, renal health, arrhythmia history and device programming. For Australian clinicians, this assessment also needs to fit the practical realities of metropolitan and rural electrophysiology care.

What appropriate therapy means

Appropriate ICD therapy refers to treatment delivered for ventricular tachycardia or ventricular fibrillation rather than for sinus tachycardia, atrial fibrillation with rapid conduction, lead noise or another sensing problem. The therapy may be antitachycardia pacing (ATP), a shock, or both. ATP can terminate some ventricular tachycardias without a painful shock, so studies that count all appropriate therapies may report higher event rates than studies that count shocks alone.

The distinction matters when discussing prognosis. A patient who receives one appropriate ATP episode is different from someone who experiences repeated high-energy shocks during an electrical storm. Device interrogation should confirm the rhythm, detection zone, electrogram quality and therapy sequence before the event is used in risk assessment.

Risk estimates also vary according to follow-up duration. A five-year cumulative incidence of appropriate therapy cannot be directly compared with a one-year shock rate. Age, cardiomyopathy type, ICD programming and the use of contemporary heart failure therapy all influence observed event rates.

Why prediction is difficult

The traditional primary prevention indication is based largely on an increased risk of sudden cardiac death, often reflected by reduced ejection fraction despite guideline-directed medical therapy. Reduced LVEF remains important, but it does not identify every patient who will develop ventricular arrhythmia. Some people with severe systolic dysfunction die from progressive pump failure or another illness without ever receiving appropriate ICD therapy.

Conversely, a patient with a modestly improved ejection fraction may retain myocardial scar and an arrhythmogenic substrate. Ischaemic scar, late gadolinium enhancement on cardiac magnetic resonance imaging, non-sustained ventricular tachycardia, frequent ventricular ectopy and genetic disease can add information that a simple LVEF threshold misses.

Modern prediction must therefore consider two competing outcomes: ventricular arrhythmia and non-arrhythmic death. A score that estimates only the chance of arrhythmia may overstate the likely benefit of an ICD in a frail patient with advanced renal disease, severe pulmonary disease or limited functional reserve.

Scores used in clinical risk assessment

The Seattle Heart Failure Model estimates overall mortality in heart failure, while the Seattle Proportional Risk Model estimates the proportion of death likely to be sudden rather than non-sudden. These tools can support shared decision-making about ICD benefit, particularly when a patient has several competing causes of death. They are not dedicated shock calculators and should not be presented as precise predictions of an individual device event.

The MADIT-ICD benefit approach combines predictors of ventricular tachyarrhythmia with predictors of non-arrhythmic mortality. Variables may include age, sex, LVEF, heart failure symptoms, atrial arrhythmia, QRS duration, renal dysfunction, diabetes and previous cerebrovascular disease, depending on the model version and population. Its value lies in framing net benefit rather than simply labelling a patient as “high risk”.

The DO-IT score was developed to estimate the likelihood of appropriate ICD therapy in primary prevention populations using clinical and electrocardiographic factors. Reported predictors include age, LVEF, non-sustained ventricular tachycardia, atrial tachyarrhythmia, kidney function and QRS characteristics. External validation is essential because performance can change across ethnic groups, health systems, device eras and treatment patterns.

Clinical variables that change the estimate

The underlying disease often provides the strongest context. Ischaemic cardiomyopathy with established infarct scar generally presents a different arrhythmic profile from non-ischaemic dilated cardiomyopathy. Hypertrophic cardiomyopathy, arrhythmogenic cardiomyopathy, cardiac sarcoidosis and inherited channelopathies require disease-specific assessment rather than reliance on a general heart failure score.

Recent clinical status is equally important. Persistent NYHA class III or IV symptoms, repeated heart failure admissions, hypotension limiting medication, worsening kidney function and frailty increase the risk of non-arrhythmic death. In contrast, stable symptoms, recovery of LVEF and good response to beta-blocker, renin–angiotensin system inhibition, mineralocorticoid receptor antagonism and sodium-glucose cotransporter 2 inhibition may alter the expected balance.

Electrocardiographic and imaging findings can refine the picture. Non-sustained VT, a broad QRS, extensive scar, inducible ventricular arrhythmia and marked ventricular ectopy may signal higher risk. Atrial fibrillation creates an additional problem: it may promote inappropriate therapy through rapid ventricular conduction, while also reflecting more advanced atrial and ventricular disease.

Device programming and modifiable shocks

The observed shock rate depends on how the ICD is programmed. Higher detection rates, longer detection intervals and ATP before shock have reduced avoidable therapies in many patients, provided programming is appropriate for the clinical substrate. Remote monitoring can identify atrial arrhythmia, lead malfunction and changes in thoracic impedance before a patient presents with repeated therapy.

A risk score should never substitute for interrogation of the device. An apparently high shock burden may reflect atrial fibrillation, lead fracture or oversensing rather than recurrent ventricular tachycardia. Conversely, a low number of shocks may be misleading if ATP has terminated several episodes.

Medication and rhythm management also influence outcomes. Optimising heart failure therapy, treating myocardial ischaemia, correcting electrolyte abnormalities and managing atrial fibrillation can reduce triggers for ventricular arrhythmia or inappropriate therapy. Catheter ablation may be considered for recurrent monomorphic ventricular tachycardia or electrical storm, especially when shocks continue despite medication.

Applying the evidence in Australia

Australian practice is shaped by access and geography. A patient living in inner Sydney, Melbourne or Brisbane may have rapid access to an electrophysiology clinic and device interrogation, while someone in regional Queensland, Western Australia or the Northern Territory may depend on outreach services, local hospitals and remote monitoring. A numerical risk estimate should be paired with a realistic plan for urgent assessment after a shock.

The local market also affects technology choices. ICD systems, remote monitoring platforms and magnetic resonance-conditional leads are accessed through public and private pathways, with availability varying between hospitals. Medicare-supported care does not remove the importance of travel, time away from work, internet connectivity or the cost of attending repeated appointments. These factors should be included in discussions about follow-up and device replacement.

Australian clinicians also need to account for national guidance, local device protocols and culturally safe communication. Aboriginal and Torres Strait Islander patients may face additional barriers to specialist access and continuity of care, particularly when treatment is delivered across large distances. A score validated overseas should be treated as decision support, not as a universal rule.

Communicating risk without false precision

Patients often ask whether an ICD will “go off”. A useful explanation separates the chance of any appropriate therapy from the chance of a painful shock, then explains that the device may first attempt ATP. Absolute risk should be expressed over a defined period, with uncertainty made clear. A score can support the conversation, but it cannot predict the exact date, rhythm or experience of a future event.

Shared decisions should include benefits, complications, generator replacement, lead management, driving implications and the possibility of deactivation near the end of life. Repeated shocks can be psychologically traumatic, and early referral for counselling or psychosocial support is appropriate when fear of therapy affects sleep, work or physical activity.

Digital safety provides a useful parallel: risk assessment is most valuable when it identifies specific vulnerabilities rather than producing a reassuring label. Discussions around secure device data show why connectivity and access controls matter in technology-dependent systems, although clinical ICD decisions must remain grounded in validated medical evidence and device-specialist review.

Building a practical risk workflow

A structured assessment can begin with the indication for implantation, cardiomyopathy type, current LVEF, NYHA class, age, renal function and competing illness. The clinician can then record non-sustained VT, atrial arrhythmia, QRS duration, scar imaging, recent admissions and medication tolerance. Applying an appropriate model should be followed by a review of calibration, validation population and endpoint definition.

The result should be documented in clinically meaningful language: estimated arrhythmic risk, estimated non-arrhythmic risk, factors that may be modified and the follow-up pathway. A patient with high arrhythmic risk and low competing mortality may have substantial expected ICD benefit. Another patient with frequent admissions, severe frailty and progressive renal disease may need a more nuanced discussion, even when the LVEF meets a conventional threshold.

For clinicians and trainees, reviewing the journal’s clinical resources can help place individual scores within the wider literature on ablation, pacing, implantable devices and cardiac electrophysiology. The strongest approach combines validated prediction tools with expert interpretation, contemporary device programming and careful attention to the patient’s goals.

Risk scores are most useful when they improve a conversation rather than end it. Before implantation and throughout follow-up, clinicians should reassess ventricular function, comorbidity, arrhythmia burden and quality of life. Patients should know how to respond after a shock, when to contact their device service and where urgent care is available. This combination of quantitative estimation and personalised planning offers a safer way to judge the likely value of primary prevention ICD therapy.